cadonilimab+chemotherapy

Phase 2Small molecule

GGuangzhou Institute of Respiratory Disease

cadonilimab+chemotherapy is one of 54 small molecule programs targeting Esophageal Squamous Cell Carcinoma. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Esophageal Squamous Cell CarcinomaNot yet recruiting

Esophageal Squamous Cell CarcinomaPhase 2

Not yet recruiting

Competition

Competitive Landscape

108 competitors in Esophageal Squamous Cell Carcinoma

#DrugCompanyPhaseTrials

Taxol

Teva

Phase 3

31 2

Beyfortus

BeiGene

Phase 3

22 3

Platinol

MMcNeil Consumer & Specialty Pharmaceuticals, a Division of McNeil-PPC, Inc.

Phase 3

33 4

Camptosar

Pfizer

Phase 3

11 5

Keytruda

Merck & Co.

Phase 3

8 6

Abraxane

Bristol-Myers Squibb

Phase 3

4 7

Tuoyi

CCoherus Oncology, Inc.

Phase 3

13 8

Opdivo

Bristol-Myers Squibb

Phase 3

2 9

Tyvyt

Innovent Biologics (Suzhou) Co. Ltd.

Phase 3

9 10

Theraplaza

BBiotech Pharmaceutical Co., Ltd.

Phase 3

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Clinical

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

Cadonilimab in Combination With Chemotherapy for Locally Advaced Esophageal Squamous Cell Carcinoma

Not yet recruiting·GGuangzhou Institute of Respiratory Disease·Phase 2·NCT05833971·43 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for cadonilimab+chemotherapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — cadonilimab+chemotherapy compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for cadonilimab+chemotherapy. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Guangzhou Institute of Respiratory Disease company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: GGuangzhou Institute of Respiratory Disease

cadonilimab+chemotherapy

Status by Indication[3][1]

Competitive Landscape

Trials by Indication[1]

Esophageal Squamous Cell Carcinoma1 trial

References

Drug Info

Quick Facts

Related News